Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
The addition of roflumilast to LABA in the treatment of patients with severe-to-very severe COPD reduces the rate of exacerbations and can be cost-effective in the UK setting. </AbstractSection> Copyright The Author(s) 2014
Year of publication: |
2014
|
---|---|
Authors: | Samyshkin, Yevgeniy ; Kotchie, Robert ; Mörk, Ann-Christin ; Briggs, Andrew ; Bateman, Eric |
Published in: |
The European Journal of Health Economics. - Springer. - Vol. 15.2014, 1, p. 69-82
|
Publisher: |
Springer |
Subject: | COPD | Cost-effectiveness analysis | Chronic-obstructive pulmonary disease | Roflumilast | Exacerbations |
Saved in:
Online Resource